Related Experiment Video

Updated: Sep 22, 2025

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.1K

Application of liquid biopsy for prognostic status of cancers and drug response

Dario Marchetti1

  • 1Division of Molecular Medicine, Department of Internal Medicine, Comprehensive Cancer Center, The University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.

Cancer Drug Resistance (Alhambra, Calif.)
|May 18, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.3K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.5K

Related Experiment Videos

Last Updated: Sep 22, 2025

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.1K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.3K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.5K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

Articles linked to this work by shared authors, journal, and citation graph.

International expert consensus on the clinical integration of circulating tumor cells in solid tumors.

European journal of cancer (Oxford, England : 1990)·2025

Comprehensive Longitudinal Linear Mixed Modeling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis.

Cancers·2025

A Melanoma Brain Metastasis CTC Signature and CTC:B-cell Clusters Associate with Secondary Liver Metastasis: A Melanoma Brain-Liver Metastasis Axis.

Cancer research communications·2025

Targeting Translation and the Cell Cycle Inversely Affects CTC Metabolism but Not Metastasis.

Cancers·2023

Deep neural network based tissue deconvolution of circulating tumor cell RNA.

Journal of translational medicine·2023

The RPL/RPS gene signature of melanoma CTCs associates with brain metastasis.

Cancer research communications·2022

ST6GAL1 promotes cancer stem-like cell-associated paclitaxel resistance through the EGFR-mTOR-SOX2/BMI1 axis in non-small cell lung cancer.

Cancer drug resistance (Alhambra, Calif.)·2026

Mitochondrial LINC01133 regulates pyroptosis and calcium homeostasis in cisplatin-resistant lung adenocarcinoma.

Cancer drug resistance (Alhambra, Calif.)·2026

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them.

Cancer drug resistance (Alhambra, Calif.)·2026

Divergent transcriptional programs and constrained metabolic states reveal selective metabolic dependencies in chemoresistant luminal breast cancer.

Cancer drug resistance (Alhambra, Calif.)·2026

Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation?

Cancer drug resistance (Alhambra, Calif.)·2026

Adenylosuccinate lyase in pancreatic ductal adenocarcinoma chemoresistance: from purine metabolism to metabolic vulnerability.

Cancer drug resistance (Alhambra, Calif.)·2026

Visualization of Collateral Lymphatic Pathways After Axillary Node Dissection in Rats Using Real-Time Fluorescent Lymphography.

Lymphatic research and biology·2026

Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study.

Blood cancer journal·2026

Rethinking Pathogenesis of Primary Sclerosing Cholangitis.

Seminars in liver disease·2026

Overuse and False Restraint in Large Language Model Recommendations for Choosing Wisely Scenarios.

Annals of internal medicine·2026

Initial Treatment for Acute Low Back Pain and Risk of Opioid Use Disorder and Overdose.

JAMA network open·2026

c-Jun N-Terminal Kinase-2 Mediates Alcohol and Corticosterone-Induced Tissue Injury at the Gut-Liver Axis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us